CanSino Biologics (06185): Application for Supplemental Registration of Manhacin Drug Accepted

Tencent Finance News, Conhino Bio (06185) announced that the company has received the "Acceptance Notification" issued by the National Medical Products Administration of China (NMPA). According to this notification, the NMPA has accepted the supplementary application of Conhino's ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 carrier) (MCV4, trade name: Menhix), expanding the applicable age range from 3 months old to 6 years old (83 months old) children to people from 3 months old to 17 years old.